Loading…
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $19M | $-47M | $-65M | $-37M | -24.3% | -29.3% | 4.4% |
| 2024 | $26M | $-51M | $-62M | $-42M | -21.6% | -22.8% | 22.5% |
| 2023 | $34M | $-50M | $-51M | $1M | -16.1% | -42.2% | 126.6% |
| 2022 | $59M | $-8M | $-22M | $-21M | -6.5% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 59.08 | 34.16 | 26.39 | 18.67 |
| Operating Revenue | - | 59.08 | 34.16 | 26.39 | 18.67 |
| Cost Of Revenue | - | - | - | 0 | 0.30 |
| Gross Profit | - | - | - | 26.39 | 18.36 |
| Operating Expense | - | 85.72 | 103.58 | 100.89 | 87.33 |
| Research And Development | - | 48.36 | 56.52 | 55.11 | 47.75 |
| Selling General And Administration | - | 24.90 | 33.31 | 30.74 | 29.22 |
| Total Expenses | - | 85.72 | 103.58 | 100.89 | 87.64 |
| Operating Income | - | -26.65 | -69.42 | -74.50 | -68.97 |
| Total Operating Income As Reported | - | -26.65 | -69.42 | -74.50 | -68.97 |
| EBITDA | - | -8.40 | -49.92 | -50.92 | -47.22 |
| Normalized EBITDA | - | -8.40 | -49.92 | -50.92 | -47.22 |
| EBIT | - | -26.65 | -69.42 | -74.50 | -68.97 |
| Interest Income | - | 0.59 | 5.06 | 3.11 | 2.66 |
| Interest Expense | 0.01 | 0 | - | - | - |
| Net Interest Income | - | 0.59 | 5.06 | 3.11 | 2.66 |
| Other Non Operating Income Expenses | 1.27 | - | 0 | -0.02 | 0.02 |
| Other Income Expense | 1.27 | - | 0 | -0.02 | 0.02 |
| Interest Income Non Operating | - | 0.59 | 5.06 | 3.11 | 2.66 |
| Interest Expense Non Operating | 0.01 | 0 | - | - | - |
| Net Non Operating Interest Income Expense | - | 0.59 | 5.06 | 3.11 | 2.66 |
| Pretax Income | - | -26.06 | -64.36 | -71.41 | -66.29 |
| Tax Provision | - | -3.73 | -13.74 | -9.38 | -1.52 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -22.33 | -50.62 | -62.03 | -64.78 |
| Net Income From Continuing And Discontinued Operation | - | -22.33 | -50.62 | -62.03 | -64.78 |
| Net Income From Continuing Operation Net Minority Interest | - | -22.33 | -50.62 | -62.03 | -64.78 |
| Net Income | - | -22.33 | -50.62 | -62.03 | -64.78 |
| Net Income Common Stockholders | - | -22.33 | -50.62 | -62.03 | -64.78 |
| Net Income Including Noncontrolling Interests | - | -22.33 | -50.62 | -62.03 | -64.78 |
| Normalized Income | - | -22.33 | -50.62 | -62.03 | -64.78 |
| Diluted NI Availto Com Stockholders | - | -22.33 | -50.62 | -62.03 | -64.78 |
| Basic Average Shares | - | 85.32 | 99.68 | 102.36 | 113.64 |
| Diluted Average Shares | - | 85.32 | 99.68 | 102.36 | 113.64 |
| Reconciled Depreciation | - | 18.25 | 19.50 | 23.58 | 21.75 |
| Reconciled Cost Of Revenue | - | - | - | 0 | 0.30 |
| Depreciation Amortization Depletion Income Statement | - | 13.05 | 13.55 | 17.41 | 12.91 |
| Depreciation And Amortization In Income Statement | - | 13.05 | 13.55 | 17.41 | 12.91 |
| General And Administrative Expense | - | 24.90 | 33.31 | 30.74 | 29.22 |
| Other Gand A | - | 24.90 | 33.31 | 30.74 | 29.22 |
| Other Operating Expenses | - | -0.59 | 0.19 | -2.37 | -2.55 |
| Amortization | - | 13.05 | 13.55 | 17.41 | 12.91 |
| Amortization Of Intangibles Income Statement | - | 13.05 | 13.55 | 17.41 | 12.91 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| OmniAb, Inc.this co. | OABI | $386M | -5.95 | 1.44 | -24.3% | -8.06 |
| Community Health Systems, Inc. | CYH | $393M | 0.77 | -0.28 | -36.5% | 5.53 |
| TruBridge, Inc. | TBRG | $391M | 89.74 | 2.20 | 2.4% | 12.54 |
| Compass Therapeutics, Inc. | CMPX | $384M | -5.77 | 1.95 | -33.8% | -5.08 |
| Benitec Biopharma Inc. | BNTC | $380M | -10.01 |
| - |
| - |
| - |
| - |
| 3.90 |
| -39.0% |
| -6.83 |
| Viemed Healthcare, Inc. | VMD | $377M | 25.26 | 2.67 | 10.6% | 7.36 |
| CapsoVision, Inc. | CV | $377M | -14.88 | 28.41 | -190.9% | -14.73 |
| Vanda Pharmaceuticals Inc. | VNDA | $376M | - | 1.15 | -67.4% | - |
| Lexeo Therapeutics, Inc. | LXEO | $375M | -3.75 | 1.52 | -40.5% | -3.28 |
| Peer Median | - | -3.75 | 2.07 | -37.7% | -3.28 | |